Krilogy Financial Boosts Stake in Boston Scientific

The investment firm increased its holdings in the medical device company during the fourth quarter.

Apr. 20, 2026 at 10:14am

Got story updates? Submit your updates here. ›

An extreme close-up of precision-engineered medical device components, conveying the complex technology and engineering behind Boston Scientific's products.Krilogy Financial's increased investment in Boston Scientific reflects growing institutional confidence in the medical device maker's future.Marlborough Today

Krilogy Financial LLC acquired a new stake of 46,220 shares in Boston Scientific Corporation (NYSE:BSX) during the fourth quarter, according to a recent SEC filing. The new position was valued at approximately $4.3 million, representing an increase in Krilogy's holdings of the medical equipment provider's stock.

Why it matters

This investment signals Krilogy Financial's confidence in Boston Scientific's future prospects. As a major player in the medical device industry, Boston Scientific's performance is closely watched by investors and analysts alike.

The details

Krilogy Financial's new stake in Boston Scientific was part of a broader trend of institutional investors and hedge funds increasing their holdings in the company during the quarter. Several other firms, including Murphy & Mullick Capital Management, Financial Consulate, and United Community Bank, also added to or initiated positions in Boston Scientific.

  • Krilogy Financial acquired the new stake in Boston Scientific during the fourth quarter of 2025.
  • The SEC filing disclosing the transaction was published on April 20, 2026.

The players

Krilogy Financial LLC

An investment management firm that acquired a new stake in Boston Scientific Corporation.

Boston Scientific Corporation

A global medical device company that develops, manufactures, and markets a broad portfolio of products used in less-invasive medical procedures.

Got photos? Submit your photos here. ›

The takeaway

Krilogy Financial's increased stake in Boston Scientific reflects the investment firm's belief in the medical device company's growth potential, underscoring the broader interest from institutional investors in this sector.